5 completed, 4 recruiting, 4 terminated, 3 unknown. 10 Phase 2, 7 Phase 1, 3 Early Phase 1.
Follow CellSight Technologies, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| [18F]-AraG PET Imaging in LA HNSCC [18F]-AraG radiotracer, Chemotherapy, Radiotherapy - Head and Neck Squamous Cell Carcinoma (HNSCC), Locally Advanced Head and Neck Squamous Cell Carcinoma | Early Phase 1 | Not yet recruiting | Indiana University | 5 | 2026-09-01 | 2026-07-22 |
| [18F]F-AraG PET Imaging in Alzheimer's Disease Drug: [18F]F-AraG (PET tracer) - Alzheimer Disease (AD) | Phase 2 | Not yet recruiting | CellSight Technologies, Inc. | 10 | 2026-05-16 | 2026-05-28 |
| Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG [18F]F-AraG - Advanced Non Small Cell Lung Cancer | Phase 2 | Recruiting | CellSight Technologies, Inc. | 20 | 2023-11-01 | 2024-10-24 |
| Test-retest Evaluation of [18F]F-AraG PET [18F]F-ARAG PET - Non-small Cell Lung Cancer | Phase 2 | Recruiting | CellSight Technologies, Inc. | 10 | 2023-10-31 | 2024-10-24 |
| A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors [18F]F-AraG - Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit | Phase 2 | Terminated | CellSight Technologies, Inc. | 9 | 2022-03-01 | 2026-03-27 |
| 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma [ 18F]F-AraG PET - Non-Hodgkin's Lymphoma | Phase 1 | Terminated | Stanford University | 2 | 2021-09-28 | 2025-02-06 |
| Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer [18F]F AraG - Non Small Cell Lung Cancer | Phase 2 | Unknown | CellSight Technologies, Inc. | 50 | 2021-04-15 | 2023-09-29 |
| Imaging Immune Activation in COVID-19 [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) - Covid19, SARS-CoV Infection | Phase 2 | Recruiting | CellSight Technologies, Inc. | 80 | 2021-04-15 | 2026-05-08 |
| [18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients [18F]F-AraG Imaging - Lung Cancer, Nonsmall Cell | Early Phase 1 | Completed | University of California, Davis | 5 | 2021-03-31 | 2025-07-02 |
| PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC) [18F]F-AraG Injection - Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 4 | 2021-02-01 | 2024-01-17 |
| Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT - Melanoma | Phase 2 | Completed | Diwakar Davar | 9 | 2020-09-02 | 2026-07-02 |
| [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy Fluorine F 18 Ara-G - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Early Phase 1 | Withdrawn | University of California, Davis | 2019-11-05 | 2022-02-01 | |
| Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer 18F-AraG - Non-small Cell Lung Cancer | Phase 1 | Unknown | University of Tennessee | 2 | 2019-07-16 | 2022-05-13 |
| Imaging Immune Activation in HIV by PET-MR [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) - HIV Infections | Phase 2 | Recruiting | CellSight Technologies, Inc. | 30 | 2018-09-21 | 2024-10-24 |
| Detection of Graft Versus Host Disease With [18F]F-AraG [18F]F-Ara-G - Graft Versus Host Disease | Phase 1 | Completed | CellSight Technologies, Inc. | 9 | 2018-05-15 | 2025-12-08 |
| T-Cell PET Imaging With [18F]F-AraG in Lung Cancer [18F]F-Ara-G, Pembrolizumab, PET/CT scan - Non-small Cell Lung Cancer | Phase 2 | Withdrawn | University of California, San Francisco | 2017-11-26 | 2019-10-21 | |
| [18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy [18F]F-AraG - Cancer | Phase 1 | Unknown | CellSight Technologies, Inc. | 30 | 2017-05-01 | 2022-12-05 |
| Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN) [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy. - Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Completed | CellSight Technologies, Inc. | 15 | 2017-05-01 | 2022-12-05 |
| Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1 Fluorine F 18 Ara-G, Positron Emission Tomography, Magnetic Resonance Imaging - Bladder Cancer | Phase 2 | Terminated | Lawrence Fong | 4 | 2017-03-07 | 2020-01-21 |
| Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans [18F]F-AraG - Cancer | Phase 1 | Completed | CellSight Technologies, Inc. | 6 | 2015-02-01 | 2018-05-17 |
Carcinoma, Non-Small-Cell Lung (7) · Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Alzheimer Disease (1) · COVID-19 (1) · Graft vs Host Disease (1) · HIV Infections (1) · Lung Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Severe Acute Respiratory Syndrome (1) · Urinary Bladder Neoplasms (1)
BaseLine dental cement (1) · Drug Therapy (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Pharmaceutical Preparations (1) · Radiotherapy (1) · pembrolizumab (1)
United States (17)
Muhammad Furqan, M.D. (2) · A. Dimitrios Colevas, MD (1) · Carina Mari Aparici, M.D. (1) · David Miklos, MD, PhD (1) · Deepak Behera, MD (1) · Diwakar Davar, MD, M.Sc (1) · Dustin Osborne, PhD (1) · Erik Mittra, M.D. (1) · Henry VanBrocklin, Ph.D. (1) · Julie Sutcliffe (1) · Lawrence Fong, MD (1) · Martin Pomper, M.D., Ph.D. (1) · Richard Zellars, MD (1) · Robert Negrin, M.D.. (1) · Robert R Flavell, M.D., Ph.D. (1)
P01CA049605 (1), P30CA093373 (1)